Corgenix sales, losses rise in FY 2007

Corgenix Medical, a cardiovascular diagnostic test kit developer, posted an upturn in sales accompanied by an increase in net losses for the year-end of its fiscal 2007.
   
For the period ending June 30, the Denver-based firm reported record sales of $7.4 million, a double-digit uptick compared with the $6.6 million in sales recorded for fiscal 2006 – an increase of 11 percent.

Net losses for the year rose to $2.4 million, compared with a net loss of $1.6 million for the prior fiscal year.

Corgenix said the net loss incurred during the 2007 fiscal year included a substantial increase in operating expenses, much of which were non-recurring expenditures due to its headquarter relocation in July 2006, in addition to significant non-operating and non-cash charges to interest expense attributable to its two 2005 convertible debt financings.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.